Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your DNA may determine how well Weight-Loss drugs work

NCT ID NCT07653412

Knowledge-focused Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at whether a person's genetic makeup can predict how much weight they will lose on the drugs semaglutide or tirzepatide. Researchers will follow 220 adults with obesity who are starting one of these medications for six months. By analyzing genetic risk scores and specific gene variants, the goal is to see if certain genetic profiles are linked to better or worse weight loss, which could one day help doctors tailor obesity treatment to each individual.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Semaglutide or Tirzepatide
What this could lead to
If successful, this could help doctors choose the most effective weight-loss drug for each person based on their genes, making treatment more personalized.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. The genetic score may not reliably predict response in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with obesity receiving semaglutide or tirzepatide as part of routine clinical care. Participants will undergo clinical, biochemical, and genetic assessment and will be followed prospectively for six months to evaluate the association between genetic risk score, obesity-related genetic variants, and weight loss response.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * BMI ≥40 kg/m² or ≥37 kg/m² with comorbidities * Initiation of semaglutide or tirzepatide Exclusion Criteria: * Prior bariatric surgery * Secondary causes of obesity * Active malignancy * Chronic pancreatitis * Family history of medullary thyroid carcinoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anti-obesity agents are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Genetic Risk Score Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anti-obesity agents Obesity (disorder) Precision medicine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Laiko General Hospital, Athens

    RECRUITING

    Athens, 11527, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.